{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:05:39Z","timestamp":1792659939804,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":853,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Yttrium-90 radioembolization (Y90RE) is a novel approach to radiation therapy for hepatocellular carcinoma (HCC), never tested in phase 2 studies. Fifty-two patients with intermediate (n.17) to advanced (n.35) HCC were prospectively recruited to assess, as the primary endpoint, efficacy of Y90RE on time-to-progression (TTP). Secondary endpoints were tumor response, safety, and overall survival (OS). All patients were Eastern Cooperative Oncology Group (ECOG) score 0-1, Child-Pugh class A-B7. Y90RE treatments aimed at a lobar delivery of 120 Gy. Retrospective dosimetric correlations were conducted and related to response. Fifty-eight treatments were performed on 52 patients. The median follow-up was 36 months. The median TTP was 11 months with no significant difference between portal vein thrombosis (PVT) versus no PVT (7 versus 13 months). The median OS was 15 months (95% confidence interval [CI], 12-18 months) with a nonsignificant trend in favor of non-PVT versus PVT patients (18 versus 13 months). Five complete responses occurred (9.6%), and the 2 year-progression rate was 62%. Objective response was 40.4%, whereas the disease control rate (78.8%) significantly affected survival (responders versus nonresponders: 18.4% versus 9.1%;<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.009). Tumor response significantly correlated with absorbed dose in target lesions (<\/jats:bold>\n                      <jats:bold>r<\/jats:bold>\n                      <jats:bold>= 0.60, 95% CI, 0.41-0.74,<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.001) and a threshold of 500 Gy predicted response (area under the curve, 0.78). Mortality at 30-90 days was 0%-3.8%. Various grades of reduction in liver function occurred within 6 months in 36.5% of patients, with no differences among stages. On multivariate analysis, tumor response was the sole variable affecting TTP (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.001) and the second affecting survival (after Child-Pugh class).<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Y90RE is an effective treatment in intermediate to advanced HCC, particularly in the case of PVT. Further prospective evaluations comparing Y90RE with conventional treatments are warranted.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.26014","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T04:25:59Z","timestamp":1345609559000},"page":"1826-1837","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":428,"title":["Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study"],"prefix":"10.1097","volume":"57","author":[{"given":"Vincenzo","family":"Mazzaferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bhoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Romito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Marchian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bongini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Lanocita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Civelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20241201","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Current concepts: hepatocellular carcinoma.","volume":"365","author":"ElSerag","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-18-20241201","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediatestage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R5-18-20241201","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R7-18-20241201","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival.","volume":"52","author":"Hilgard","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R8-18-20241201","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jvir.2010.04.012","article-title":"Radioembolization with use of yttrium90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.","volume":"21","author":"Inarrairaegui","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"R9-18-20241201","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona2000 EASL conference. European Association for the Study of the Liver.","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"R10-18-20241201","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R11-18-20241201","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1245\/s10434-010-0940-4","article-title":"Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus.","volume":"17","author":"Shi","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R12-18-20241201","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment.","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"R13-18-20241201","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.RVI.0000184594.01661.81","article-title":"Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.","volume":"16","author":"Salem","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"R15-18-20241201","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.","volume":"54","author":"Sangro","year":"2011","journal-title":"HEPATOLOGY"},{"key":"R16-18-20241201","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R18-18-20241201","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium90 microspheres: a comprehensive report of longterm outcomes.","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"R19-18-20241201","first-page":"168","article-title":"Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.","volume":"55","author":"Chiesa","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R20-18-20241201","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a twocohort study.","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"R21-18-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"R23-18-20241201","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","article-title":"Cell cycle dependent and scheduledependent antitumor effects of sorafenib combined with radiation.","volume":"67","author":"Plastaras","year":"2007","journal-title":"Cancer Res"},{"key":"R24-18-20241201","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma.","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R25-18-20241201","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1053\/j.gastro.2011.04.054","article-title":"Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.","volume":"141","author":"Memon","year":"2011","journal-title":"Gastroenterology"},{"key":"R26-18-20241201","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2967\/jnumed.111.094235","article-title":"Dosimetry based on 99mTcmacroaggregated albumin SPECTCT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Yloaded glass microspheres: preliminary results.","volume":"53","author":"Garin","year":"2012","journal-title":"J Nucl Med"},{"key":"R27-18-20241201","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","article-title":"Radioembolization for hepatocellular carcinoma.","volume":"56","author":"Sangro","year":"2012","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26014","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201305000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:47:26Z","timestamp":1733042846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201305000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954789.793461371","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}